Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphosys Ag ADR (NQ: MOR ) 18.20 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 18.20 Bid (Size) 18.03 (3) Ask (Size) 18.47 (1) Prev. Close 18.20 Today's Range 18.20 - 18.20 52wk Range 4.185 - 19.50 Shares Outstanding 32,890,046 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders June 20, 2024 From Halper Sadeh LLC Via Business Wire MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders June 20, 2024 From MorphoSys AG Via Business Wire Performance YTD +88.80% +88.80% 1 Month -1.67% -1.67% 3 Month +0.94% +0.94% 6 Month +101.10% +101.10% 1 Year +135.14% +135.14% More News Read More Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders June 19, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's After-Market Session May 27, 2024 Via Benzinga MorphoSys: Q4 Earnings Insights March 13, 2024 Via Benzinga Earnings Outlook For MorphoSys March 12, 2024 Via Benzinga Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024 March 07, 2024 Via ACCESSWIRE MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024 April 30, 2024 Via InvestorPlace MorphoSys AG Reports First Quarter 2024 Financial Results April 29, 2024 From MorphoSys AG Via Business Wire MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib April 29, 2024 Via Benzinga Exposures Product Safety MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting April 24, 2024 Via ACCESSWIRE Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends April 23, 2024 Via Benzinga MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 From MorphoSys AG Via Business Wire MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 Via ACCESSWIRE MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act March 21, 2024 Via ACCESSWIRE MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From MorphoSys AG Via Business Wire Earnings Scheduled For March 13, 2024 March 13, 2024 Via Benzinga 5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 March 09, 2024 Via Talk Markets 3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise March 07, 2024 Via InvestorPlace Exit Now! 3 Biotech Stocks to Sell in February 2024 February 21, 2024 Via InvestorPlace Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B February 06, 2024 Via Benzinga Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion February 05, 2024 Via Investor's Business Daily Why Is MorphoSys (MOR) Stock Up 50% Today? February 05, 2024 Via InvestorPlace Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 05, 2024 Via Benzinga MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer February 05, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
